{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:55:13Z","timestamp":1790517313538,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.semcancer.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T06:56:25Z","timestamp":1470466585000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["NF-\u03baB deregulation in splenic marginal zone lymphoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Valeria","family":"Spina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2016.08.002_bib0005","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"April (17)","key":"10.1016\/j.semcancer.2016.08.002_bib0010","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"7\u201312","key":"10.1016\/j.semcancer.2016.08.002_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2119\/2005-00001.Stamatopoulos","article-title":"Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma","volume":"10","author":"Stamatopoulos","year":"2004","journal-title":"Mol. Med."},{"issue":"April (8)","key":"10.1016\/j.semcancer.2016.08.002_bib0020","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/1078-0432.CCR-15-1170","article-title":"An immunogenetic signature of ongoing antigen interactions in splenic marginal zone lymphoma expressing IGHV1-2*04 receptors","volume":"22","author":"Bikos","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"July (7)","key":"10.1016\/j.semcancer.2016.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulinheavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"issue":"September (9)","key":"10.1016\/j.semcancer.2016.08.002_bib0030","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-celllymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2016.08.002_bib0035","doi-asserted-by":"crossref","first-page":"e24939","DOI":"10.1371\/journal.pone.0024939","article-title":"Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas","volume":"6","author":"Robledo","year":"2011","journal-title":"PLoS One"},{"issue":"September (6)","key":"10.1016\/j.semcancer.2016.08.002_bib0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.semcancer.2016.08.002_bib0045","doi-asserted-by":"crossref","first-page":"e44997","DOI":"10.1371\/journal.pone.0044997","article-title":"An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma","volume":"7","author":"Watkins","year":"2012","journal-title":"PLoS One"},{"issue":"June (12)","key":"10.1016\/j.semcancer.2016.08.002_bib0050","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Integruppo Italiano Linfomi Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"October (2)","key":"10.1016\/j.semcancer.2016.08.002_bib0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Splenic Marginal Zone Lymphoma Study Group. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"July (7)","key":"10.1016\/j.semcancer.2016.08.002_bib0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.11635","article-title":"NOTCH2 mutations in marginal zone lymphoma","volume":"93","author":"Tr\u00f8en","year":"2008","journal-title":"Haematologica"},{"issue":"August (9)","key":"10.1016\/j.semcancer.2016.08.002_bib0065","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J. Exp. Med."},{"issue":"August (9)","key":"10.1016\/j.semcancer.2016.08.002_bib0070","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J. Exp. Med."},{"issue":"December (12)","key":"10.1016\/j.semcancer.2016.08.002_bib0075","doi-asserted-by":"crossref","first-page":"e83244","DOI":"10.1371\/journal.pone.0083244","article-title":"Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma","volume":"8","author":"Parry","year":"2013","journal-title":"PLoS One"},{"issue":"June (6)","key":"10.1016\/j.semcancer.2016.08.002_bib0080","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Mart\u00ednez","year":"2014","journal-title":"Leukemia"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2016.08.002_bib0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"issue":"September (18)","key":"10.1016\/j.semcancer.2016.08.002_bib0090","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"October","key":"10.1016\/j.semcancer.2016.08.002_bib0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s12885-015-1766-z","article-title":"Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations","volume":"15","author":"Peveling-Oberhag","year":"2015","journal-title":"BMC Cancer"},{"issue":"November (11)","key":"10.1016\/j.semcancer.2016.08.002_bib0100","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2656","article-title":"The follicular versus marginal zone B lymphocyte cell fate decision","volume":"9","author":"Pillai","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"March (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-(B in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol. Rev."},{"issue":"November (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1600-065X.2011.01059.x","article-title":"Non-canonical NF-(B signaling activation and regulation: principles and perspectives","volume":"244","author":"Razani","year":"2011","journal-title":"Immunol. Rev."},{"issue":"March (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-\u03baB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol. Rev."},{"issue":"November (18)","key":"10.1016\/j.semcancer.2016.08.002_bib0120","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-(B pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"September (5)","key":"10.1016\/j.semcancer.2016.08.002_bib0125","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2004-10-3898","article-title":"Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis","volume":"106","author":"Ruiz-Ballesteros","year":"2005","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2016.08.002_bib0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.20090765","article-title":"A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme","volume":"206","author":"Malynn","year":"2009","journal-title":"J. Exp. Med."},{"issue":"May (20)","key":"10.1016\/j.semcancer.2016.08.002_bib0135","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"issue":"November (5)","key":"10.1016\/j.semcancer.2016.08.002_bib0140","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.semcancer.2016.08.002_bib0145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and T.L.R. signaling pathways are recurrently targeted by genetic changes in splenic marginalzone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"issue":"June (7247)","key":"10.1016\/j.semcancer.2016.08.002_bib0150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"September (39)","key":"10.1016\/j.semcancer.2016.08.002_bib0155","doi-asserted-by":"crossref","first-page":"26960","DOI":"10.1074\/jbc.M114.598763","article-title":"I\u03baB kinase \u03b2 (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor \u03baB (NF\u03baB) signaling","volume":"289","author":"Kai","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"January (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-(B-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"issue":"December (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/asheducation-2014.1.113","article-title":"Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis","volume":"2014","author":"Rossi","year":"2014","journal-title":"Hematolo. Am. Soc. Hematol. Educ. Program."},{"issue":"January (1)","key":"10.1016\/j.semcancer.2016.08.002_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphomaentities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2016.08.002_bib0175","first-page":"252318","article-title":"CD79B and MYD88 mutations in splenic marginal zone lymphoma","volume":"2013","author":"Tr\u00f8en","year":"2013","journal-title":"ISRN Oncol."},{"issue":"March (13)","key":"10.1016\/j.semcancer.2016.08.002_bib0180","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"March (11)","key":"10.1016\/j.semcancer.2016.08.002_bib0185","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.semcancer.2016.08.002_bib0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/modpathol.2014.120","article-title":"MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma","volume":"28","author":"Hamadeh","year":"2015","journal-title":"Mod. Pathol."},{"issue":"May (5)","key":"10.1016\/j.semcancer.2016.08.002_bib0195","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma","volume":"39","author":"Martinez-Lopez","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"February (7332)","key":"10.1016\/j.semcancer.2016.08.002_bib0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"September (9)","key":"10.1016\/j.semcancer.2016.08.002_bib0205","first-page":"a003004","article-title":"Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1","volume":"2","author":"Thome","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"March (5870)","key":"10.1016\/j.semcancer.2016.08.002_bib0210","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"October (10)","key":"10.1016\/j.semcancer.2016.08.002_bib0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc3582","article-title":"Kr\u00fcppel-like factors in cancer","volume":"13","author":"Tetreault","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"February (2)","key":"10.1016\/j.semcancer.2016.08.002_bib0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zonelymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"issue":"August (2)","key":"10.1016\/j.semcancer.2016.08.002_bib0225","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.immuni.2007.07.012","article-title":"Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs","volume":"27","author":"Xie","year":"2007","journal-title":"Immunity"},{"issue":"August (31)","key":"10.1016\/j.semcancer.2016.08.002_bib0230","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1073\/pnas.0805186105","article-title":"NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells","volume":"105","author":"Sasaki","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"October (10)","key":"10.1016\/j.semcancer.2016.08.002_bib0235","doi-asserted-by":"crossref","first-page":"e1000518","DOI":"10.1371\/journal.pbio.1000518","article-title":"Non-canonical NF-(B activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2","volume":"8","author":"Conze","year":"2010","journal-title":"PLoS Biol."},{"issue":"January (2)","key":"10.1016\/j.semcancer.2016.08.002_bib0240","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1073\/pnas.1013168108","article-title":"Kr\u00fcppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression","volume":"108","author":"Hart","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"January (2)","key":"10.1016\/j.semcancer.2016.08.002_bib0245","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1073\/pnas.1012858108","article-title":"B cell homeostasis and plasma cell homing controlled by Kr\u00fcppel-like factor 2","volume":"108","author":"Winkelmann","year":"2011","journal-title":"Proc Natl Acad Sci U. S. A."},{"issue":"December (24)","key":"10.1016\/j.semcancer.2016.08.002_bib0250","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1182\/blood-2010-12-325944","article-title":"CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2signaling","volume":"118","author":"Hampel","year":"2011","journal-title":"Blood"},{"issue":"March (12)","key":"10.1016\/j.semcancer.2016.08.002_bib0255","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2014-08-596247","article-title":"DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features","volume":"125","author":"Arribas","year":"2015","journal-title":"Blood"},{"issue":"July (7)","key":"10.1016\/j.semcancer.2016.08.002_bib0260","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/leu.2012.29","article-title":"Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection","volume":"26","author":"Peveling-Oberhag","year":"2012","journal-title":"Leukemia"},{"issue":"July (7)","key":"10.1016\/j.semcancer.2016.08.002_bib0265","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/modpathol.2012.220","article-title":"Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling","volume":"26","author":"Arribas","year":"2013","journal-title":"Mod. Pathol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T07:40:36Z","timestamp":1568274036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X16300335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":53,"alternative-id":["S1044579X16300335"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.08.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NF-\u03baB deregulation in splenic marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}